This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
PETACC-6 was a randomized phase 3 treatment trial evaluating capecitabine with or without oxaliplatin as part of multimodality therapy for patients with locally advanced rectal cancer.
| Feature | PETACC-6 |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Condition | Colorectal Cancer |
| Allocation | Randomized |
| Masking | None |
| Primary purpose | Treatment |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
2. Clinical Question
The trial evaluated whether adding oxaliplatin to a capecitabine-based treatment approach affected outcomes in patients with locally advanced rectal cancer receiving chemotherapy and radiation therapy before surgery.
Population
Patients with locally advanced rectal cancer.
Intervention
Capecitabine with oxaliplatin.
Comparator
Capecitabine without oxaliplatin.
Primary question
Does the randomized treatment comparison affect disease-free survival?
3. Trial Design
Capecitabine + Oxaliplatin
Patients received capecitabine with oxaliplatin as part of the study treatment strategy.
Capecitabine
Patients received capecitabine without oxaliplatin as the comparison treatment strategy.
4. Endpoints
| Endpoint | Registry definition |
|---|---|
| Disease-free survival | Primary endpoint. |
The registry identifies disease-free survival as the primary endpoint but does not provide additional endpoint definitions or posted statistical results in the ClinicalTrials.gov record.
5. Statistical Methodology
The primary statistical focus of PETACC-6 is a randomized comparison using disease-free survival as the primary endpoint. Disease-free survival is a time-to-event endpoint that typically measures the time from a defined starting point until disease recurrence, progression, or another prespecified event.
Time-to-event methods allow patients without an observed event at the analysis cutoff to contribute follow-up information through censoring.
Randomization
Randomization creates comparable treatment groups in expectation and allows differences in outcomes to be attributed to treatment assignment under the assumptions of the trial design.
Time-to-event analysis
Disease-free survival analyses commonly use methods such as Kaplan-Meier estimation, log-rank comparisons, and Cox proportional-hazards models. These approaches account for differing follow-up times among participants.
Hazard ratios
A hazard ratio, when used, compares estimated instantaneous event rates between randomized groups over follow-up. It is a relative measure and does not directly describe absolute differences in event probabilities.
6. Planned Analysis
The registry identifies disease-free survival as the primary endpoint. For a time-to-event endpoint of this type, analysis would typically involve estimation of disease-free survival distributions and comparison of randomized groups using survival-analysis methods.
No formal statistical analyses were posted to ClinicalTrials.gov for this registry record.
7. Statistical Methods Explained
Why is disease-free survival analyzed as a time-to-event endpoint?
Disease-free survival records when an event occurs rather than only whether an event occurred. This preserves information from patients followed for different lengths of time.
What does censoring mean in survival analysis?
Censoring occurs when a patient's event status is not observed beyond a certain point. The patient contributes available follow-up information up to that time without being counted as having an event.
Why is randomization important?
Randomization balances known and unknown prognostic factors on average between treatment groups, supporting an unbiased comparison of outcomes.
Why are confidence intervals important?
A confidence interval describes uncertainty around an estimated treatment effect. Narrow intervals generally indicate greater precision than wide intervals.
What does a hazard ratio represent?
A hazard ratio compares estimated event rates between groups over time. It does not directly equal a percentage of patients benefiting or the probability that an individual patient will experience an outcome.
8. Limitations
- Limited registry reporting: The ClinicalTrials.gov record does not report posted statistical analyses or outcome estimates for the primary endpoint.
- Endpoint interpretation: Disease-free survival depends on event definitions, follow-up duration, and censoring rules.
- Model assumptions: Survival models such as Cox regression rely on assumptions that should be evaluated when results are available.
- Absolute versus relative effects: Relative measures alone do not describe the complete clinical pattern of benefit or risk.
- Trial population: Results from randomized trials apply most directly to patients meeting the study eligibility criteria.
9. Why This Trial Matters Statistically
PETACC-6 illustrates several important concepts in clinical trial methodology: randomized comparisons, multimodality treatment strategies, and the use of disease-free survival as a primary time-to-event endpoint.
| Concept | How it appears in PETACC-6 |
|---|---|
| Randomization | Phase 3 randomized comparison |
| Time-to-event analysis | Disease-free survival as the primary endpoint |
| Comparator design | Capecitabine with versus without oxaliplatin |
| Clinical endpoint selection | Assessment of disease-related outcomes after treatment |
| Statistical interpretation | Requires consideration of effect estimates, uncertainty, and follow-up |
10. Sources
- ClinicalTrials.gov: NCT00766155.
- PubMed: PETACC-6 publication record.
Continue through the Clinical Biostats knowledge graph
Explore additional clinical trial analyses, statistical tutorials, and calculators.
11. Record Summary
PETACC-6 is a phase 3 randomized clinical trial evaluating capecitabine with or without oxaliplatin in locally advanced rectal cancer. The registry identifies disease-free survival as the primary endpoint, but the ClinicalTrials.gov record does not provide posted statistical analyses or outcome estimates. The statistical framework of the trial centers on randomized comparison and time-to-event methodology for evaluating disease-related outcomes.